Skip to main content

Table 1 Effect of number of immunizations, antigen dose, and adjuvant dose on HBsAg-specific response a

From: Intranasal Immunization of Mice with CpG DNA Induces Strong Systemic and Mucosal Responses That Are Influenced by Other Mucosal Adjuvants and Antigen Distribution

  Adjuvant Number of Responders (of 5 immunized mice)
N° Doses HBsAg CT CpG Post-prime Post-boost 1 Post-boost 2 Post-challenge
1 1    0 N/Db N/D 0
1 1 1   0 N/D N/D 3
1 1   1 0 N/D N/D 1
1 1 1 1 0 N/D N/D 4
3 1    0 0 0 0
3 1 1   0 0 0 5
3 1   1 0 0 1 3
3 1 1 1 0 0 2 5
3 1 10   1 2 4 N/D
3 1   10 0 3 5 N/D
3 1   50 0 1 3 N/D
3 1 1 10 1 4 5 N/D
3 10 1   5 5 5 N/D
3 10 10   3 4 5 N/D
3 10   1 3 5 5 N/D
3 10   10 2 5 5 N/D
3 10   50 2 5 5 N/D
3 10 1 1 5 5 5 N/D
3 10 1 10 5 5 5 N/D
  1. aBALB/c mice were immunized by intranasal (IN) inhalation of 1 or 10 µg of purified hepatitis B surface antigen (HBsAg) alone (none) or with 1, 10 or 50 µg cholera toxin (CT) and/or CpG-containing oligodeoxynucleotides (CpG) in a total volume of 20 µl. Some mice were boosted in an identical manner at 4 and 8 weeks. Other mice that failed to develop anti-HBs, such as those immunized with 1 µg HBsAg alone or with low dose adjuvant (1 µg), were challenged by intramuscular (IM) injection of 1 µg HBsAg without adjuvant, to determine if immune response had been primed. HBsAg-specific antibody titers were determined by ELISA in plasma taken 4 weeks after final immunization or 2 weeks after challenge. Titers were defined as the highest plasma dilution resulting in an absorbance value two times that of nonimmune plasma, with a cut-off value of 0.05. Values shown represent the number of responding mice (titers > 100).
  2. bN/D, not determined